ABCD1 and multiple sclerosis: Pioglitazone has also demonstrated the ability to reduce neurodegeneration and neuroinflammation in two models of experimental autoimmune encephalomyelitis (EAE), a highly reproducible and well-established preclinical model used in multiple sclerosis (MS) research [78], and to improve motor function in an ATP binding cassette subfamily D member 1/2 (Abcd1/Abcd2) double knockout mouse model of ALD [79].